Gluconeogenesis was studied in hepatocytes isolated from phenobarbital-pretreated rats fasted for 24 h. In closed vial incubations, glucose production from lactate (20 mmol/l) and pyruvate (2 mmol/l), alanine (20 mmol/l) or glutamine (20 mmol/l) was suppressed by about 30-45 %, although glycerol metabolism was not affected. In hepatocytes perifused with lactate and pyruvate (ratio 10: 1), glucose production was inhibited by 50 %, even at low gluconeogenic flux. From the determination of gluconeogenic intermediates at several steady states of gluconeogenic flux, we have found a single relationship between phosphoenolpyruvate and the rate of glucose production (iglucose), and two different curves between cytosolic oxaloacetate and Jgjucose in controls and in phenobarbital-pretreated hepatocytes. By using 3-mercaptopicolinate to determine the flux control coefficient of phosphoenolpyruvate carboxykinase we found that phenobarbital pretreatment led to an increase in this coefficient from 0.3 (controls) to 0.8 (phenobarbital group). These observations were confirmed by the finding that the activity of phosphoenolpyruvate carboxykinase was decreased by 500% after phenobarbital treatment. Hence we conclude that the inhibitory effect of phenobarbital on gluconeogenesis is due, at least partly, to a decrease in the flux through phosphoenolpyruvate carboxykinase.
INTRODUCTION
Chronic phenobarbital treatment is associated with an increase in smooth endoplasmic reticulum (SER) membranes and with modifications of some liver microsomal enzymes located in the SER; in particular, an enhancement of NADPH-utilizing mixed function oxidation, the major pathway of detoxification of drugs and many endogenous substances, is observed (Conney, 1967; Remmer, 1972; Schulte-Hermann, 1974) .
A decrease in plasma glucose and an improvement in sensitivity to insulin have been shown in diabetic patients after chronic phenobarbital treatment (Lathela et al., 1984 (Lathela et al., , 1985 (Lathela et al., , 1986 . Such a fall in plasma glucose after chronic phenobarbital treatment may be due to a decrease in the glucogenic rate, since excessive hepatic glucose production is one of the major features in diabetic patients (Best et al., 1982) . Karvonen et al. (1989) have shown in lean female Zucker rats that phenobarbital stimulates the activities of NADPH-dependent enzymes, such as glucose-6-phosphate dehydrogenase and malic enzyme. Orrenius and coworkers (Orrenius et al., 1965; Orrenius & Ericsson, 1966) have reported that chronic phenobarbital treatment in rats decreases the activity of the glucose-6-phosphatase (EC 3.1.3.9) bound to SER. Scholz et al. (1973) , using the non-recirculating perfused liver model, have observed inhibition of gluconeogenesis from lactate following stimulation by aminopyrine of the NADPHutilizing mixed function oxidation system that is induced by phenobarbital pretreatment in rats.
The purpose of the present work was to investigate the effects of phenobarbital pretreatment on gIuconeogenesis in isolated hepatocytes. Moreover, by measuring the intracellular gluconeogenic intermediates it is possible to locate the effect of such chronic treatment, since many steps have been reported to be affected: glucose-6-phosphatase (Orrenius & Ericsson, 1966; Karvonen et al., 1987) , pyruvate carboxylase (EC 6.4.1.1) (Scholz et al., 1973) and NADPH-dependent enzymes (Karvonen et at., 1989) . We found a dramatic decrease in glucose synthesis from physiological substrates, e.g. lactate/pyruvate, alanine and glutamine, although glycerol metabolism was not affected. The inhibitory effect on gluconeogenesis was obtained without addition of exogenous substrates (e.g. aminopyrine) for NADPH-utilizing mixed function oxidation. Using perifused hepatocytes, we report here that the main gluconeogenic step influenced by such pretreatment may be phosphoenolpyruvate carboxykinase (EC 4.1.1.32).
MATERIALS AND METHODS
Male Wistar rats fed with stock pellets given ad libitum were used for this study. Chronic phenobarbital induction was obtained with an oral dose of 100 mg/kg per day for 15 days as reported previously by Marshall & McLean (1969) . Drinking water was fully available to all animals, but for those receiving oral sodium phenobarbital, an aqueous solution of the drug in tap water was the only source of water. The water intake, given either as water or as a 1 mg/ml solution of sodium phenobarbital, was approx. 10 ml/100 g per day (giving a dose of 100 mg/kg per day). During the 15 days of treatment, the weight gained by the phenobarbital-treated rats was the same as in the control group. As reported previously by Marshall & McLean (1969) , pretreated rats were only lethargic for the first 2 days. On the day of experiment, both groups had the same weight: controls, 245 + 13 g; phenobarbital-treated, 244 + 12 g.
After 15 days of sodium phenobarbital pretreatment, rats (200-250 g) were fasted for 24 h. They were then anaesthetized with sodium pentobarbital intraperitoneally (112.5 mg/kg for control rats; 155 mg/kg for phenobarbital-pretreated rats). Hepatocytes were isolated according to the method of Berry & Friend (1969) , as modified by Groen et al. (1982a) .
Chronic phenobarbital induction of microsomal protein was shown by determination of levels of cytochrome P-450, a mixed function oxidase. Cytochrome P-450 was measured by the method of Omura & Sato (1964) Zuurendonk & Tager (1974) and modified by Groen et al. (1982a) . The concentration of cytosolic oxaloacetate was subsequently calculated from the cytosolic malate concentration and the lactate/pyruvate ratio, assuming equilibrium for lactate dehydrogenase (EC 1.1.1.27) (Williamson et al., 1967) .
Phosphoenolpyruvate carboxykinase activity was determined after 15 days of sodium phenobarbital pretreatment. Enzyme activity was measured as described by Chang & Lane (1966) in frozen liver samples from 24 h-fasted rats. Protein concentration was determined using the Bio-Rad protein assay (Bio-Lab., Miinchen, Germany), with BSA as standard.
All metabolites were measured either spectrophotometrically or fluorimetrically using standard enzymic methods (Bergmeyer, 1970 When hepatocytes were incubated in closed vials without any exogenous substrate, glucose production from endogenous substrate was inhibited (19.25 + 1.20 versus 12.42 + 0.59 ,tmol/g dry mass after 1 h for the control and pretreated groups respectively, P < 0.001). Glucose production was linear over the last 45 min of incubation and the calculated fluxes were inhibited by phenobarbital: 0.34+0.02,umol/min per g dry mass for control rats versus 0.22 + 0.01 ,umol/min per g for pretreated rats (P < 0.00 1). This effect could be due either to decreased endogenous substrate production (e.g. a decrease in amino acid production from proteolysis), or to a decrease in their utilization in the gluconeogenic pathway.
The inhibitory effects of phenobarbital treatment on glucose production with various gluconeogenic substrates are summarized in Table 1 Cells from rats treated (*) or not (El) with phenobarbital were perifused as described in Fig. 1 . At each steady state, 0.7 ml samples of the cell suspension were removed from the perifusion vessel and centrifuged through a layer of silicone oil into HC104 (10%, w/v treated, n = 6; c: control, n = 4; treated, n = 6; d: control, n = 2; treated, n = 5; e: control, n = 5; treated, n = 6;f: control, n = 5; treated, n = 6.)
intermediates can be determined. By plotting intermediate concentrations and the gluconeogenic flux, some information concerning the step(s) involved in the inhibitory effect can be obtained. We chose lactate and pyruvate (in a ratio of 10:1) as substrates because of their great physiological importance in gluconeogenesis.
Effect of chronic phenobarbital treatment on gluconeogenesis from lactate+pyruvate in perifused hepatocytes These experiments were carried out with oleate (0.1 mmol/l) in order to activate pyruvate carboxylase by providing acetyl-CoA, its allosteric activator (Groen et al., 1983) . In similar conditions these authors found a maximal value for the rate glucose production (Qgucose) of 4.7 ,umol/min per g dry mass, which is very close to our results (Fig. 1) . As shown in Fig. 1 , a stronger inhibitory effect was observed when hepatocytes were perifused (50 %) than in those incubated in closed vials (30%). This inhibitory effect was present even at low substrate concentrations (0.15 mmol/1). Moreover, the highest gluconeogenic rate was obtained at a lactate concentration of 1.2 mmol/l (Fig. 1) [iglucose = 4.99 + 0.3 ,tmol/min per g dry mass (n = 5) for the control experiment; Jglucose = 2.46 + 0.16,umol/min per g dry mass (n = 8) for the phenobarbital-treated group (P < 0.001)].
The relationships between some intracellular intermediates and gluconeogenic flux are shown in Fig. 2 [Oxaloacetate] (pM) Fig. 3 . Relationship between the rate of gluconeogenesis from lactate+ pyruvate and the concentration of cytosolic oxaloacetate Cells from rats treated (*) or not (El) with phenobarbital were perifused as described in Fig. 1 . At each steady state, 0.7 ml samples of the cell suspension were removed from the perifusion chamber for rapid separation of mitochondria and cytosol by the digitonin fractionation procedure (see the Materials and methods section (Fig. 4c) . Addition of glucagon also increased glucose production in the phenobarbital group, but the highest rate (3.79 + 0.25 ,umol/min per g dry mass) did not reach that in controls without glucagon (4.99 + 0.3 ,umol/min per g dry mass) (Fig. 4a) and was far below the rate after glucagon addition in controls (8.24 ,umol/min per g dry mass, n = 1) (Fig. 4c) . It must be pointed out that glucagon addition increased glucose production in phenobarbital-treated cells by about 50 % (2.46 to 3.79 ,umol/min per g dry mass) (Fig.  4b) , whereas for the same rate of glucose production in control hepatocytes (2.5 ,umol/min per g dry mass), the effect of glucagon is smaller (Groen et al., 1983) or absent (Fig. 4c) .
We can also postulate an effect of phenobarbital treatment on phosphoenolpyruvate carboxykinase, as already indicated in Fig. 3 , 1974; Jomain-Baum et al., 1976) , a procedure also used by Groen and co-workers (Groen et al., 1982b Rigoulet et al., 1987) . Fig. 5 gives the results of this experiment, in which increasing concentrations of the inhibitor were infused in the presence of glucagon and saturating concentrations of lactate plus pyruvate (10: 1) in hepatocytes from pretreated or untreated rats. Assuming equilibration of 3-MPA across the plasma membrane, the flux control coefficient of phosphoenolpyruvate carboxykinase can be calculated from the following equation (Groen et al., 1982b; Rigoulet et al., 1987) :
in which J denotes gluconeogenic flux, I is the concentration of the inhibitor and K, is the inhibition constant (3 ,umol/l; JomainBaum et al., 1976) . This experiment was performed in duplicate (one is shown in Fig. 5 ). The calculation yielded values for C of 0.32 and 0.34 for the control group and 0.83 and 0.86 for the phenobarbital-treated group. It should be noted that the control values are very close to that previously reported (0.28) by Rigoulet et al. (1987) . Hence it appears that chronic phenobarbital treatment increases dramatically the flux control coefficient of phosphoenolpyruvate carboxykinase, explaining a major part of the inhibitory effect on gluconeogenesis from lactate plus pyruvate (10: 1). The effect of phenobarbital pretreatment on phosphoenolpyruvate carboxykinase was confirmed by the measurement of phosphoenolpyruvate carboxykinase activity, which was decreased by 50 % in the phenobarbital group [7.7 + 0.5 nmol/min per mg of protein (n = 4) versus 16 + 1.53 nmol/min per mg (n = 5) for the control group (P < 0.002)].
DISCUSSION
Our results clearly show an inhibition of gluconeogenesis in hepatocytes isolated from rats pretreated for 15 days with Vol. 280 667 phenobarbital (100 mg/kg per day in drinking water). This inhibition of gluconeogenesis in vitro was not due to a direct effect of phenobarbital, either used for anaesthesia of the animals or added in the drinking water for the chronic treatment, since Scholz et al. (1966) have reported a rapid elimination of phenobarbital during the rat liver perfusion and isolation procedure. Thus the inhibitory effect on gluconeogenesis results mainly from a chronic exposure and not from a direct effect of this drug.
The decrease in the gluconeogenic flux is not due to decreased cell viability in the phenobarbital-treated group during the isolation procedure or closed flask incubation, for two reasons. First, in closed flask incubation and in perifused hepatocytes no difference was found with regard to total nucleotide content: cytosolic and mitochondrial ATP/ADP ratios were slightly but significantly higher in the phenobarbital group (results not shown). Secondly, the inhibitory effect was not found when glycerol was used as gluconeogenic substrate. To our knowledge, this is the first report of inhibition of gluconeogenesis due to chronic phenobarbital in isolated hepatocytes. Scholz et al. (1973) reported inhibition of gluconeogenesis in perfused livers isolated from phenobarbital-pretreated rats only when perfused in the presence of aminopyrine (0.2 mmol/l), a substrate for NADPH-utilizing mixed-function oxidation.
Glucose-6-phosphatase, which catalyses the final step in the gluconeogenesis pathway, is a SER-bound enzyme. Changes in its activity following enzyme induction have been reported in the literature, although the results are controversial. Pretreatment with phenobarbital in normal rats, obese or lean female Zucker rats, and lean or obese (ob/ob) mice appears to decrease the activity of this enzyme (Orrenius & Ericsson, 1966; Karvonen etal., 1987) , whereas in non-insulin-dependent diabetic humans its activity increases . In our conditions such an explanation (i.e. modulation of glucose-6-phosphatase activity) is not likely, since the flux control coefficient of this step is very low (less than 2%; Groen et al., 1986; Rigoulet et al., 1987) . Moreover, it is clear from our data (Fig. 2a) that changes in glucose-6-phosphatase activity do not explain the inhibitory effect of phenobarbital, since we found a single relationship between glucose-6-phosphate concentration and gluconeogenic flux both with and without phenobarbital pretreatment.
Microsomal protein induction due to phenobarbital pretreatment leads to an increase in cytochrome P-450 content and to an increase in NADPH-utilizing mixed function oxidation in liver cells. Therefore, when substrates such as aminopyrine are present, the NADPH-utilizing system is enhanced and the NADPH/ NADP+ ratio is decreased. Such a decrease in the cellular reducing state has been linked to an effect on carbohydrate metabolism (Junge & Brand, 1975) , either by an increase in the pentose pathway or by an increase in malic enzyme flux, both leading to NADPH formation. As reported by Junge & Brand (1975) (Fig. 2c) Scholz et al. (1973) was found only at saturating lactate concentrations, whereas we report a 35 % inhibition at a lactate concentration of only 0.15 mmol/l. Moreover, an effect via a futile cycle involving malic enzyme would lead to a single relationship between cytosolic malate or oxaloacetate and glucose flux regardless of chronic phenobarbital treatment, which it is not the case (Fig. 3) . In contrast with experiments reported by Scholz et al. (1973) , in our perifusion experiments there were no added substrates, such as aminopyrine, that would be metabolized by NADPH-utilizing mixed function oxidases. Hence this explanation cannot entirely account for our results.
The results presented here allow us to propose another explanation involving the pyruvate/phosphoenolpyruvate cycle. In Fig. 2(e) it is clearly apparent that a unique relationship was observed between phosphoenolpyruvate and the flux of glucose formation in both groups of hepatocytes. This confirms that in our conditions the main effect of phenobarbital treatment on the gluconeogenic pathway is located upstream from phosphoenolpyruvate. This is in good agreement with our results in closed flask incubations (Table 1) , where gluconeogenesis from lactate/ pyruvate, alanine or glutamine was decreased by phenobarbital treatment, whereas glycerol metabolism was not affected. Indeed, glycerol metabolism is mainly controlled by the redox state (Williamson et al., 1971; Berry et al., 1973; Leverve et al., 1985 Leverve et al., , 1986 , and phosphoenolpyruvate/pyruvate cycling is not involved in this pathway. As reported by Groen et al. (1983 Groen et al. ( , 1986 , the main controlling steps of the gluconeogenic pathway from lactate are pyruvate carboxylase, phosphoenolpyruvate carboxykinase and pyruvate kinase, since transport of pyruvate across the plasma membrane (Denton & Halestrap, 1979) and the mitochondrial membrane (Groen et al., 1983) and the transport of oxaloacetate (in the form of aspartate) to the cytosol (Williamson, 1976) have high capacities. Moreover, the two distinct relationships between cytosolic oxaloacetate concentration and glucose flux (Fig. 3) (Groen et al., 1983 . The percentage stimulation by glucagon in the phenobarbital-treated group was higher than that in the control cells at a similar glucose flux, as reported by Groen et al. (1986) and confirmed here. Hence it could be proposed that phenobarbital treatment enhances the pyruvate kinase flux, leading to a greater inhibitory effect of glucagon on this step. This result suggests some effect of chronic phenobarbital treatment which activates phosphoenolpyruvate/pyruvate cycling. However, a pure effect via the pyruvate kinase step cannot alone explain the inhibitory effect of phenobarbital since, as reported in Fig. 1 , in cells from phenobarbital-treated animals the flux in the presence of glucagon does not reach that in controls and is far below the glucagon-stimulated flux reported in the literature (Groen et al., 1983; Rigoulet et al., 1987) (Groen & Tager, 1988) .
Our results show that the flux control coefficient of phosphoenolpyruvate carboxykinase is much higher in the phenobarbital-treated cells (0.80) (Cimbala et al., 1982; Beale et al., 1982 Beale et al., , 1984 Lyonnet et al., 1988) . Insulin and glucagon regulate liver phosphoenolpyruvate carboxykinase by modifying its gene transcription Granner & Andreone, 1985) . We suggest that phenobarbital treatment decreases phosphoenolpyruvate carboxykinase gene transcription by affecting the insulin/glucagon ratio.
